Sign In
Buy IBIO
$1.84
+0.0800 (+4.55%)
At Close: Jun 03, 2026
iBio Announces $26 Million Private Placement
07:00am, Friday, 09'th Jan 2026
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement
Critical Survey: PyroGenesis Canada (NASDAQ:PYRGF) & iBio (NYSE:IBIO)
01:42am, Thursday, 18'th Dec 2025
iBio (NYSE: IBIO - Get Free Report) and PyroGenesis Canada (NASDAQ: PYRGF - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies b
iBio to Participate in the 8th Annual Evercore Healthcare Conference
04:15pm, Monday, 24'th Nov 2025
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Heal
iBio, Inc. (IBIO) Reports Q1 Loss
06:15pm, Wednesday, 12'th Nov 2025
iBio, Inc. (IBIO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.46 per share a year ago.
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 12'th Nov 2025
Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Pres
Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinu
Critical Comparison: iBio (IBIO) vs. Its Rivals
01:53am, Sunday, 26'th Oct 2025
iBio (NASDAQ: IBIO - Get Free Report) is one of 450 publicly-traded companies in the "Pharmaceutical Preparations" industry, but how does it weigh in compared to its competitors? We will compare iBio
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
07:00am, Thursday, 23'rd Oct 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual He
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
07:30am, Friday, 05'th Sep 2025
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30,
iBio Announces Closing of $50 Million Public Offering
07:00am, Monday, 25'th Aug 2025
Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asse
iBio Announces Pricing of $50 Million Public Offering
08:01am, Tuesday, 19'th Aug 2025
SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “
iBio Announces Proposed Public Offering
04:01pm, Monday, 18'th Aug 2025
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the �
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
07:00am, Tuesday, 24'th Jun 2025
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
04:15pm, Monday, 23'rd Jun 2025
Review of promising Myostatin and Activin E antibody data iBio to announce 3 rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWS
